NCT03710863 - Safety and Tolerability of Oral CM082 in Patients With wAMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 22, 2018

Primary Completion Date

January 1, 2022

Study Completion Date

January 1, 2022

Conditions

Age-Related Macular Degeneration

Interventions

DRUG

CM082

Subjects will receive CM082 orally twice daily for two weeks followed by two weeks off in four-week cycles. The starting dose of 25mg BID will be increased by 100% to the maximum dose of 50mg BID.The treatment period is tentatively set at 1 year.

Trial Locations (1)

430060

RECRUITING

Renmin Hospital of Wuhan University, Hubei General Hospital, Wuhan